A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

This study has been completed.

Study NCT00002067. Last updated on October 1, 2007. Information provided by Bristol-Myers Squibb

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
Official Title ^†	Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
Brief Summary	To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.
Detailed Description
Study Phase	Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Double-Blind
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Anorexia Cachexia HIV Infections
Intervention ^†	Drug: Megestrol acetate
MEDLINE PMIDs	9066597
Links	BMS Clinical Trials Disclosure For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†
Start Date ^†
Completion Date
Eligibility Criteria ^†	Inclusion Criteria Patient must have: Confirmed diagnosis of AIDS (CDC definition). Documented weight loss or anorexia. Life expectancy = or > 20 weeks. The perception that the weight loss is a detriment to their well-being. Ability to provide informed consent, read and write English. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Dementia or evidence of mental incompetence which would preclude compliance with the protocol. Severe diarrhea defined as 5 or more watery stools per day for at least 7 days. Active uncontrolled systemic infections at the start of treatment. Patients may not be entered for at least 2 weeks after acute infection. Clinical or radiologic evidence of ascites or pleural effusions. Patients with the following are excluded: Obstruction to food intake or impaired digestive/absorptive functions. Contraindications to megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis). Inability to consent or be available for close follow-up. Active systemic infections at the start of treatment. Clinical or radiologic evidence of ascites or pleural effusions. Patients who have been hospitalized or have suffered an exacerbation of their illness associated with weight loss within the past 2 weeks are excluded. Menstruating female patients are excluded. Prior Medication: Excluded: Corticosteroids. Anabolic steroids. Marijuana. Megestrol acetate. Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.) Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain. Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.) History of substance abuse and questionable current and future abstinence.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00002067
Organization ID	025B
Secondary IDs ^††	MEG8809
Study Sponsor ^†	Bristol-Myers Squibb
Collaborators ^††
Investigators ^†
Information Provided By	Bristol-Myers Squibb
Verification Date	October 2007
First Received Date ^†	November 2, 1999
Last Updated Date	October 1, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.